Since S100A12 is a pro-inflammatory factor secreted by granulocytes, it is reasonable to speculate that the inflammatory response during plaque progression is not affected by the various anti-inflammatory mechanisms mediated by HDL-C in populations with lower levels of HDL-C, thus leading to a stronger correlation between S100A12 and PAD risk. The gene discussed is S100A12; the disease is peripheral arterial disease.